Follistatin-344 vs ACE-031: Two Approaches to Blocking Myostatin
Follistatin-344 traps myostatin directly while ACE-031 blocks its receptor: this comparison reviews 2 published studies, mechanisms, and why safety signals differ between the two research compounds.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Follistatin-344 and ACE-031 are the two most-studied myostatin-pathway inhibitors in muscle-growth research, but they block the same signaling axis through entirely different molecular strategies — one is a ligand trap, the other neutralizes the receptor itself. Researchers comparing the two compounds are typically trying to decide which inhibition strategy best matches a given experimental model, since ligand-level and receptor-level blockade produce overlapping but non-identical effects on skeletal muscle.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Follistatin-344 inhibits myostatin and activin A by binding the ligands directly, while ACE-031 is a soluble activin receptor type IIB (ActRIIB) fusion protein that intercepts the same ligands before they reach the receptor; both produce muscle hypertrophy in preclinical models, but ACE-031's receptor-trap mechanism has shown a distinct off-target vascular safety signal that halted its own clinical program.
TL;DR:
- Follistatin-344 is a full-length follistatin isoform that binds myostatin/activin A directly ("ligand trap") and has been studied primarily in bodybuilding-associated case series and preclinical hypertrophy models.
- ACE-031 is a recombinant ActRIIB-Fc fusion protein ("receptor trap") that showed significant lean mass and contractile force gains in a non-human primate study.
- Both compounds converge on blocking the same TGF-β superfamily signaling axis (myostatin/activin → ActRIIB → Smad2/3), but by intercepting the pathway at different points.
- Human safety data diverge sharply: follistatin-344 has documented ocular adverse events (central serous chorioretinopathy) in a case series of bodybuilders, while ACE-031's clinical program was halted after vascular adverse effects (telangiectasia, epistaxis) in Duchenne muscular dystrophy trials.
- Neither compound holds FDA approval or 503A/503B compounding status; both remain investigational/research-use compounds.
Follistatin-344: mechanism and evidence base
Follistatin-344 is the longer of the two principal naturally occurring follistatin isoforms, distinguished from follistatin-315 by a C-terminal extension that reduces its affinity for cell-surface heparan sulfate proteoglycans and allows it to circulate more freely in research contexts. Mechanistically, it functions as a competitive antagonist of myostatin (GDF-8) and activin A — both members of the TGF-β superfamily that normally act as negative regulators of skeletal muscle mass. By binding these ligands before they can engage the activin receptor type IIB (ActRIIB), follistatin-344 prevents downstream Smad2/3 phosphorylation, effectively lifting the molecular brake on muscle protein synthesis and satellite cell proliferation.
The clearest published human evidence for follistatin-344's biological activity is, somewhat unusually, a safety signal rather than an efficacy trial. A retrospective case series (PMID 32671599) documented 11 male bodybuilding athletes, mean age 36.8 ± 8.1 years, who developed central serous chorioretinopathy (CSCR) after high-dose subcutaneous injection of complete 1 mg follistatin-344 vials. All 11 patients developed CSCR; single-injection patients showed complete resolution of subretinal fluid within an average of 2.3 ± 0.7 months, while patients with a history of multiple injections experienced recurrent episodes. The authors concluded follistatin-344 should be considered a risk factor for CSCR and recommended that ophthalmologic history-taking include performance-enhancing peptide use. Full compound data is available on the Follistatin-344 library profile.
ACE-031: mechanism and evidence base
ACE-031 takes a structurally different approach to the same signaling problem. It is a soluble fusion protein pairing the extracellular domain of the activin receptor type IIB with a human IgG1 Fc fragment, engineered to act as a decoy receptor that circulates in serum and sequesters myostatin and activin A before they ever reach an endogenous ActRIIB receptor on muscle tissue. Because it captures both principal ActRIIB ligands rather than a single one, ACE-031 has been characterized in the literature as a broader-spectrum inhibitor of the pathway than ligand-specific antagonists.
The most directly comparable efficacy data for ACE-031 comes from a non-human primate study (PMID 41686840) in the common marmoset (Callithrix jacchus). Marmosets received ACE-031 or vehicle control for 14 weeks; the treatment group showed a significant time-by-treatment interaction for lean body mass, with measurable gains from baseline that were absent in vehicle-treated controls. Biceps brachii samples showed significant cross-sectional hypertrophy in both Type I (slow-twitch oxidative) and Type II (fast-twitch glycolytic) fiber populations, and ex vivo testing of the extensor digitorum longus (EDL) muscle showed increased absolute and specific force production — indicating the mass gain translated into functional contractile improvement, not just tissue volume. Full compound data is available on the ACE-031 library profile.
Separately from this primate study, ACE-031 also progressed into human Phase II trials for Duchenne muscular dystrophy, where it produced increased lean muscle mass but was discontinued after adverse vascular effects — including telangiectasia (visible small blood vessel dilation) and epistaxis (nosebleeds) — were observed, a safety signal attributed to ActRIIB's broader role in vascular endothelial regulation beyond skeletal muscle.
Side-by-side comparison
| Follistatin-344 | ACE-031 | |
|---|---|---|
| Inhibition strategy | Ligand trap (binds myostatin/activin A) | Receptor trap (ActRIIB-Fc fusion decoy) |
| Structure | 344-amino-acid follistatin isoform | ActRIIB extracellular domain + human IgG1 Fc |
| Molecular weight | ~41,847 g/mol | ~100,000 g/mol |
| Primary human evidence | Retrospective adverse-event case series (bodybuilders) | Phase II DMD trial (halted) |
| Preclinical efficacy model | Rodent/in vitro hypertrophy studies | Non-human primate (marmoset) lean mass and force study |
| Documented adverse signal | Central serous chorioretinopathy | Telangiectasia, epistaxis |
| Regulatory/compounding status | Not FDA-approved; not on 503A Bulks List | Not FDA-approved; clinical program discontinued |
| Research category | Performance/Muscle | Performance/Muscle |
Differential research applications
Researchers studying ligand-specific blockade — isolating the effects of myostatin and activin A without perturbing other ActRIIB-adjacent signaling — have generally gravitated toward follistatin isoforms like follistatin-344, since the ligand trap approach leaves the receptor itself available for other endogenous binding partners. This distinction matters in experimental designs probing muscle-specific hypertrophy pathways versus systemic ActRIIB biology.
By contrast, ACE-031's receptor-level blockade captures a broader share of ActRIIB signaling, which is part of why its non-human primate data showed such a clear lean-mass and force-production signal — and also likely why its human trials surfaced vascular effects that ligand-specific approaches have not reported at comparable frequency. Researchers modeling comprehensive ActRIIB pathway blockade, rather than isolating a single ligand, have used ACE-031 and related ActRIIB-Fc constructs as the reference compound class. Anyone comparing pharmacokinetic exposure windows across these two mechanisms of action can cross-reference clearance profiles using the half-life comparison tool.
Molecular size is another practical factor in study design. Follistatin-344, at roughly 41,847 g/mol, is substantially smaller than the ACE-031 fusion protein, which — as an Fc-linked construct — sits closer to 100,000 g/mol. That size difference has implications for tissue distribution and clearance: Fc-fusion proteins are generally retained in circulation longer than smaller peptides because of neonatal Fc receptor (FcRn) recycling, a pharmacokinetic property shared with many therapeutic antibody constructs. Researchers designing comparative dosing schedules in animal models have cited this distinction when explaining why ACE-031's marmoset study used a sustained 14-week administration window rather than the shorter dosing intervals typical of smaller myostatin-pathway peptides. The purity lookup tool and molecular weight reference can help researchers cross-check formulation data for both compound classes.
It's also worth noting that "myostatin inhibitor" is often used loosely in the research literature to describe compounds with meaningfully different selectivity profiles. Follistatin-344's dual myostatin/activin A antagonism means it can affect activin-dependent processes elsewhere in the body — including reproductive endocrinology, where activin signaling plays a regulatory role — a consideration that does not straightforwardly apply to receptor-trap constructs with different binding kinetics. ACE-031's broader ActRIIB blockade, meanwhile, does not distinguish between myostatin and activin A at the receptor level, which is one proposed explanation for its more pronounced off-target vascular findings in human trials, since ActRIIB signaling is not restricted to skeletal muscle tissue.
Regulatory and compounding status
Neither compound holds FDA approval for any indication, and neither appears on the FDA's Section 503A Bulk Drug Substances List, meaning neither is currently eligible for compounding pharmacy preparation under standard 503A pathways. ACE-031's clinical development for Duchenne muscular dystrophy was discontinued following the vascular adverse event findings described above, and no subsequent sponsor has advanced it through later-phase human trials. Follistatin-344 has not entered controlled human clinical trials; the only published human data available is the observational CSCR case series, which was not a prospective safety or efficacy study. Both compounds remain squarely in the research-use category, with published evidence limited to preclinical models (rodent and non-human primate) and, in follistatin-344's case, uncontrolled observational reports.
Cited studies
- PMID 32671599 — "Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series" (2020).
- PMID 41686840 — "ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus)" (2026). DOI: https://doi.org/10.1111/j.1365-2249.2012.04654.x
Frequently asked questions
Q: What is the main difference between follistatin-344 and ACE-031?
A: Follistatin-344 binds myostatin and activin A directly as a ligand trap, while ACE-031 is a soluble ActRIIB receptor fusion protein that intercepts the same ligands before they reach the endogenous receptor. Both converge on blocking the same downstream Smad2/3 signaling but act at different points in the pathway.
Q: Is ACE-031 safe for research use?
A: ACE-031's Phase II clinical trial in Duchenne muscular dystrophy was discontinued after researchers observed vascular adverse effects including telangiectasia and epistaxis. This safety signal is documented in the published clinical literature and should inform any research protocol design.
Q: Has follistatin-344 been tested in controlled human trials?
A: No. The only published human data available on follistatin-344 comes from a retrospective observational case series of 11 bodybuilding athletes who developed central serous chorioretinopathy after high-dose injection (PMID 32671599); this was not a prospective clinical trial.
Q: Are follistatin-344 or ACE-031 approved for compounding under FDA 503A rules?
A: No. Neither compound currently appears on the FDA's Section 503A Bulk Drug Substances List, and neither holds FDA approval for any human indication.
Q: Why did researchers see muscle fiber gains in both Type I and Type II fibers with ACE-031?
A: The non-human primate study (PMID 41686840) found ACE-031 produced significant cross-sectional hypertrophy in both slow-twitch oxidative (Type I) and fast-twitch glycolytic (Type II) muscle fibers, consistent with ActRIIB blockade acting broadly across fiber types rather than selectively on one contractile subtype.
See also:
- Best Peptides for Muscle and Performance Research — broader roundup that includes follistatin-344 alongside other muscle-research compounds.
- IGF-1 LR3, DES(1-3) IGF-1, and PEG-MGF: IGF-1 Analogue Cluster — a related comparison of growth-factor analogues used in muscle hypertrophy research.
- CJC-1295 vs CJC-1295 with DAC: Pulsatile vs Sustained GH Release — covers a complementary growth hormone axis pathway also studied in muscle research contexts.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.